Hy-Tech Engineers, Symbiotec Pharmalab, and Skyways Air Services See Contrasting Market Debuts

Shares of Hy-Tech Engineers, Skyways Air Services, and Symbiotec Pharmalab recorded contrasting market debuts on Tuesday. Hy-Tech Engineers emerged as the strongest performer among the three IPO listings, while Symbiotec Pharmalab registered gains following a muted opening, and Skyways Air Services listed at a discount.

Hy-Tech Engineers debuted at a 41.5 per cent premium on the NSE at ₹75, compared to its offer price of ₹53. On the BSE, the stock listed at ₹72, marking a 35.8 per cent premium. Following the debut, the stock was locked in its upper circuit of ₹78.75 and traded at ₹75.59 on the NSE and BSE, respectively. The ₹135.73 crore IPO had a price band of ₹50-53 per equity share and received an overall subscription of 244.41 times, with the QIB portion booked 255.77 times, the NII portion 402.29 times, and the retail portion 170.58 times. The Maharashtra-based company had revised its IPO size by trimming the fresh issue to ₹60 crore and increasing the offer for sale (OFS) component.

Symbiotec Pharmalab experienced a muted debut, opening flat at ₹988 on the NSE, which matched its IPO price. On the BSE, the stock started trading at ₹978.20. By midday at 12.36 pm, the stock traded at ₹1,165 on the NSE after reaching an intraday high of ₹1,180. The IPO comprised a fresh issue of shares worth up to ₹150 crore and an OFS component amounting to ₹1,607 crore, with a price band of ₹938-988 per equity share, valuing the company at around ₹6,350 crore at the upper limit.

Skyways Air Services listed at a 10 per cent discount on both the NSE and BSE at ₹124 each, compared to its IPO price of ₹138. At the time of writing, the stock traded at ₹128.40 on the NSE, slightly above its listing price. The IPO consisted of a fresh issue of up to 2.89 crore shares and an OFS of up to 1.33 crore shares by promoters and existing shareholders, with the price band fixed at ₹131-138 per share.

Market analysts noted the different fundamentals driving these performances. According to Shivani Nyati, Head of Wealth at Swastika Investmart Ltd., Symbiotec Pharmalab’s flat listing reflected muted market interest at its valuation, noting the company operates in a specialised business with high entry barriers. For Skyways Air Services, Nyati stated that the weak listing showed soft sentiment despite strong IPO demand, pointing to the company's thin profit margins and debt reduction plans. Regarding Hy-Tech Engineers, Nyati highlighted strong investor demand, healthy operating margins of around 22 per cent, net margins over 11.5 per cent, and a reduction in company debt as factors supporting its strong market performance.

"These contrasting market debuts highlight how investors are closely evaluating individual company fundamentals, profit margins, and debt profiles rather than relying solely on overall IPO subscription numbers. Companies with strong operating metrics and clear debt-reduction strategies are naturally commanding better post-listing momentum. For retail and institutional investors alike, understanding the balance between issue valuation and long-term financial health remains critical when navigating primary market listings." — Dr. Shishir Gupta, Founder & CEO, StartupLanes